Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 8-K (Current Report)
Report Date: March 11, 2024
Reporting Period: Quarter and full year ended December 31, 2023
This filing serves as a notification that the company has announced its financial results for the period ended December 31, 2023. The detailed financial data is contained within the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only confirms the announcement of results for the quarter and year ended December 31, 2023.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. It notes that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 11, 2024) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02.
- Check for any forward-looking statements or updated guidance within the full press release text.
- Confirm the company's status as an emerging growth company (indicated as checked in the filing).